Please login to the form below

Not currently logged in

Arcus Biosciences

This page shows the latest Arcus Biosciences news and features for those working in and with pharma, biotech and healthcare.

Gilead agrees $21bn buyout of Immunomedics

Gilead agrees $21bn buyout of Immunomedics

In May, Gilead also announced its intent to partner with Arcus Biosciences on the development and commercialisation of next-generation cancer immunotherapies. ... This included gaining rights to zimberelimab, an investigational anti-PD-1 monoclonal

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Acquisition. $463m. Precision BioSciences/. Gilead Sciences. ARCUS technology; targeting in vivo elimination of. ... Gilead has also agreed a strategic collaboration with Precision BioSciences worth $445m in potential milestones; in addition there are

  • Pharma deals continue to slide Pharma deals continue to slide

    Arcus, a privately owned US immuno-oncology company, may have to do the same following its deal to license a monoclonal antibody from the Chinese companies WuXi Biologics and Gloria Pharmaceuticals. ... 1, 410 (upfront 80). WuXi Biologics and Gloria

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...